120 related articles for article (PubMed ID: 23567961)
41. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
42. A FLT3-inhibitory constituent from the rhizomes of Anemarrhena asphodeloides.
Han SY; Chin YW
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):445-8. PubMed ID: 20846091
[TBL] [Abstract][Full Text] [Related]
43. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
Nordigården A; Zetterblad J; Trinks C; Gréen H; Eliasson P; Druid P; Lotfi K; Rönnstrand L; Walz TM; Jönsson JI
Br J Haematol; 2011 Oct; 155(2):198-208. PubMed ID: 21848891
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core.
Xu J; Ong EHQ; Hill J; Chen A; Chai CLL
Bioorg Med Chem; 2014 Dec; 22(23):6625-6637. PubMed ID: 25456387
[TBL] [Abstract][Full Text] [Related]
45. Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations.
Zhang G; Zhang W; Shen C; Nan J; Chen M; Lai S; Zhong J; Li B; Wang T; Wang Y; Yang S; Li L
Bioorg Med Chem Lett; 2020 Nov; 30(22):127532. PubMed ID: 32891702
[TBL] [Abstract][Full Text] [Related]
46. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
47. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
48. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
49. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
50. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
51. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
52. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
53. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
54. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
[TBL] [Abstract][Full Text] [Related]
56. Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C
Oh C; Kim H; Kang JS; Yun J; Sim J; Kim HM; Han G
Bioorg Med Chem Lett; 2017 Feb; 27(3):496-500. PubMed ID: 28043794
[TBL] [Abstract][Full Text] [Related]
57. Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.
Malínková V; Řezníčková E; Jorda R; Gucký T; Kryštof V
Bioorg Med Chem; 2017 Dec; 25(24):6523-6535. PubMed ID: 29089259
[TBL] [Abstract][Full Text] [Related]
58. Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit.
Nakano H; Hasegawa T; Imamura R; Saito N; Kojima H; Okabe T; Nagano T
Bioorg Med Chem Lett; 2016 May; 26(9):2370-4. PubMed ID: 26995531
[TBL] [Abstract][Full Text] [Related]
59. Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors.
Abutayeh RF; Almaliti J; Taha MO
Med Chem; 2020; 16(3):403-412. PubMed ID: 30931863
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors.
Grimm SH; Gagestein B; Keijzer JF; Liu N; Wijdeven RH; Lenselink EB; Tuin AW; van den Nieuwendijk AMCH; van Westen GJP; van Boeckel CAA; Overkleeft HS; Neefjes J; van der Stelt M
Bioorg Med Chem; 2019 Mar; 27(5):692-699. PubMed ID: 30661740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]